A syngeneic spontaneous zebrafish model of tp53-deficient, EGFRvIII, and PI3KCAH1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapse in vivo
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Canada
- Department of Molecular Genetics, University of Toronto, Canada
- Knight Cancer Institute, Oregon Health & Science University, United States
- Department of Pediatrics, Papé Research Institute, Oregon Health & Science University, United States
Figures
Figure 1 with 3 supplements
her4.1-driven over-expression of patient-relevant oncogenes drives glial-derived brain tumor formation in syngeneic tp53 loss-of-function mutant zebrafish.
(A) Schematic of modeling strategy where linearized transgene vectors with the zebrafish her4.1 promoter driving human EGFRvIII, human PI3KCAH1047R, and mScarlet fluorescent proteins are co-injected at the one-cell stage into syngeneic (CG1 strain) tp53-/- mutant zebrafish embryos. Starting at 15 days post fertilization (dpf), mosaic-injected zebrafish were screened for CNS tumor formation, indicated by mScarlet expression in the brain region of live zebrafish. Co-injection of gfap:GFP linearized transgene is used to assess glial-specific cell fate specification in vivo. (B) her4.1:mScarlet and gfap:GFP expression in the anterior CNS of mosaic-injected syngeneic (CG1 strain) tp53-/- zebrafish at 30 dpf. (C) Whole brain dissected from a p53EPS mosaic-injected zebrafish at 30 dpf. (D) Cumulative frequencies of mScarlet+ CNS lesions in syngeneic tp53-/- mutant (CG1tp53-/-) and wild-type (CG1) zebrafish injected at the one-cell stage with her4.1:EGFRvIII (E), her4.1:PI3KCAH1047R (P), and/or her4.1:mScarlet (S). (E) Syngeneic (CG1 strain) zebrafish at 30 dpf engrafted with her4.1:mScarlet+/gfap:GFP+ brain tumor cells, following primary transplantation (1T) at 2 dpf into the embryonic brain ventricle. (F) Whole brain dissected from engrafted syngeneic host (CG1) zebrafish at 30 dpf. (G) Fluorescence-activated cell sorting (FACS) plot of bulk syngeneic host brain following primary transplant (1T) of her4.1:EGFRvIII + her4.1:PI3KCAH1047R + her4.1:mScarlet + gfap:GFP brain tumor cells. (H–O) Histological staining of uninjected control (H–K) and p53EPS tumor-burdened brains (L–O). (H, L) Hematoxylin and eosin (H&E) staining of coronal sections highlighting telecephalon and diencephalon regions of representative control (H) and p53EPS (L) brains. (I, M) Proliferating cell nuclear antigen (PCNA) staining of control (I) and p53EPS (M) brain sections. (J, N) Phosphorylated-ERK (p-ERK) staining and quantifications reveal increased MAPK signaling pathway activation in p53EPS tumors (p<0.001, n=3 independent tumor sections). (K, O) Phosphorylated-Akt (p-Akt) staining and quantifications reveal increased Akt signaling pathway activity in p53EPS tumors (p=0.007, n=3 independent tumor sections). Scare bars represent 50 μm.
Figure 1—figure supplement 1
Intertumoral heterogeneity in p53EPS-induced tumors.
Sample screens of p53EPS-injected fish showing distinct tumor initiation sites and varying degrees of mScarlet fluorescent intensity. Tumors predominantly arise in the optic tectum/mesencephalon region with a subset appearing in the telencephalon/diencephalon region. Distinct tumors did not arise in the cerebellum/rhombencephalon regions over the course of our experiments.
Figure 1—figure supplement 2
Hematoxylin and eosin (H&E) staining of three independent p53EPS tumors.
Scale bars represent 50 μm.
Figure 1—figure supplement 3
her4.1-driven over-expression of KRASG12D + PI3KCAH1047R drives glial-derived brain tumor formation in syngeneic tp53 loss-of-function mutant zebrafish.
(A) her4.1:mScarlet and gfap:GFP expression in the anterior CNS of 30 days post fertilization (dpf) syngeneic (CG1) tp53-/- zebrafish injected at the one-cell stage with linearized her4.1:KRASG12D + her4.1:PI3KCAH1047R + her4.1:EGFP + gfap:mScarlet transgenes. (B) Whole brain dissected from mosaic-injected her4.1:KRASG12D + her4.1:PI3KCAH1047R + her4.1:EGFP zebrafish at 30 dpf. (C) Cumulative frequencies of EGFP+ brain lesions in syngeneic tp53-/- mutant (CG1tp53-/-) and wild-type (CG1) zebrafish injected at the one-cell stage with her4.1:KRASG12D (K), her4.1:PI3KCAH1047R (P), and/or her4.1:EGFP (G). (D) Immunohistochemical staining of proliferating cell nuclear antigen (PCNA), phosphorylated-ERK (p-ERK), and phosphorylated-AKT (p-AKT) on her4.1:KRASG12D + her4.1:PI3KCAH1047R + her4.1:EGFP tumor section. Quantification of p-ERK and p-AKT positive cells within total field. Scale bars represent 50 μm.
Figure 2 with 2 supplements
RNA expression analysis establishes enrichment of mesenchymal glioblastoma and inflammation signatures in p53EPS model.
(A) Principal component analysis (PCA) of mRNA sequencing from whole control-injected brains (CTRL), p53EPS, and p53KPS tumor-burdened brains. (B) Heatmap of normalized counts for genes upregulated in p53EPS tumor-burdened brains (log2foldChange>2, padj<0.05), compared to whole control-injected brains (CTRL). A selected list of upregulated transcripts is indicated. (C) Gene set enrichment analysis (GSEA) plots of published gene signatures for mesenchymal subtype glioblastoma for genes differentially regulated in p53EPS compared to control-injected brains (McLendon et al., 2008; Wang et al., 2017). Normalized enrichment scores (NES) and nominal p-values are indicated. (D) Bar plot of NES from GSEA of Hallmark gene sets (Villanueva et al., 2011). (E) Volcano plots of differentially expressed genes between sorted mScarlet+ p53EPS tumor cells and control-injected whole brain tissue (CTRL WB), as well as between sorted mScarlet-negative cells from p53EPS tumor-burdened brains and control-injected whole brains (CTRL WB). (F) her4.1:mScarlet and rag2:EGFP expression in live zebrafish with a p53EPS tumor at 30 days post fertilization (dpf). (G) Fluorescence-activated cell sorting (FACS) plot of p53EPS brain with rag2:EGFP co-expression from (F). (H, I) her4.1:mScarlet and mpeg1.1:EGFP expression in live zebrafish with a p53EPS tumor at 30 dpf.
Figure 2—figure supplement 1
Gene set enrichment analysis (GSEA) plots of published gene signatures for alternative molecular subtypes of human glioblastoma and medulloblastoma for genes differentially regulated in p53EPS compared to control-injected brains (Cavalli et al., 2017; McLendon et al., 2008; Wang et al., 2017).
Normalized enrichment scores (NES) and nominal p-values are indicated.
Figure 2—figure supplement 2
Quantitative real-time PCR analysis of neural stem cell (NSC) genes and genes associated with inflammatory gene expression signatures identified using bulk RNA sequencing.
Gene expression in pooled her4.1:mScarlet+/gfap:EGFP+ fluorescence-activated cell sorting (FACS)-sorted cells relative to non-tumor control brain tissue. *p<0.01, **p<0.001, Student’s t-test.
Figure 3 with 1 supplement
p53EPS recruits activated microglia/macrophages at early stages of tumor initiation.
(A–C) Neutral red staining of p53EPS mScarlet tumor-negative (A) and mScarlet tumor-positive brains (B, C) at 10 days post fertilization (dpf). Neutral red foci in early-stage lesions are highlighted with arrows and are indicative of phagocytic cells. (D) Whole brain with p53EPS-induced tumor in a transgenic Tg(tnfa:EGFP) zebrafish at 20 dpf. (E) Z-stack projection of live confocal imaging of p53EPS tumor in transgenic Tg(tnfa:EGFP) background. (F–K) Z-stack projections of control uninjected (F–H) and p53EPS brains (I–K) at 5 dpf (F ,I), 7 dpf (G, J), and 9 dpf (H, K) in transgenic Tg(mpeg1.1:EGFP) background. White arrows highlight an early-stage p53EPS lesion and associated mpeg:EGFP+ cells. (L) Z-stack projections of two independent p53EPS brains at 12 dpf in transgenic Tg(mpeg1.1:EGFP) background. (M) Quantification of tumor-associated mpeg1.1:EGFP+ cells with overlapping and/or internalized her4.1:mScarlet+ punctae (n=3 independent tumors).
Figure 3—figure supplement 1
Gene set enrichment analysis (GSEA) plots of established gene signatures for classical M1 polarized macrophages (Classical_M1_VS_Alternative_M2_Macrophage_UP), compared to alternative M2 macrophages (Classical_M1_VS_Alternative_M2_Macrophage_DN).
GSEA plots of macrophage-specific gene expression at early (DAY3 UP) and late (DAY3 Down) time points of stimulation with macrophage colony stimulating factor (MCSF). Normalized enrichment scores (NES) and nominal p-values are indicated.
Figure 4 with 2 supplements
Inflammation-associated irf7 and irf8 inhibit p53EPS formation in vivo.
(A–C) Primary (1°) control (A), irf7 CRISPR/Cas9 (B), and irf8 CRISPR/Cas9 (C) injected p53EPS at 30 days post fertilization (dpf). (D) p53EPS incidence at 30 dpf in control (n=3 independent experiments, 108 zebrafish), irf7 CRISPR/Cas9 (***p<0.0001, Fisher’s exact test, n=2 independent experiments, 31 zebrafish), and irf8 CRISPR/Cas9 (*p=0.0155, Fisher’s exact test, n=2 independent experiments, 36 total injected zebrafish). (E) Representative fluorescent in situ hybridization (FISH) images of whole mount control p53EPG (E) EGFRvIII + PI3KCAH1047 + EGFP and p53EPG + irf7 CRISPR/Cas9-injected zebrafish at 8 dpf. p53EPG (EGFP, magenta) and irf7 (green) images represent Z-stack projections through tumor lesions (11 optical sections each). Merged images represent single optical sections at two spatially separated levels within control and irf7 knock-down tumors. DAPI staining (blue) is used to label nuclei. White arrowheads highlight irf7 expression specific to the tumor microenvironment (TME). Scale bars represent 10 μm. (F) Tg(her4.1:Cas9-2A-EGFP) expression at 30 dpf. (G) mScarlet+ p53EPS at 30 dpf in Tg(her4.1:Cas9-2A-EGFP) injected with irf7 guide RNAs (gRNAs) at the one-cell stage. (H) p53EPS incidence at 30 dpf in Tg(her4.1:Cas9-2A-EGFP)-negative gRNA-injected control siblings, and Tg(her4.1:Cas9-2A-EGFP) zebrafish injected at the one-cell stage with irf7 or irf8 gRNAs. n.s. not significant, Fisher’s exact test.
Figure 4—figure supplement 1
Quantitative real-time PCR analysis of irf7 CRISPR/Cas9-injected (A) and irf8 CRISPR/Cas9-injected p53EPS (B).
Gene expression is represented relative to control p53EPS tumor-burdened whole brains. At least five tumor-burdened brains were pooled for each cohort and expression was normalized to mScarlet mRNA expression to account for differences in tumor size. *p<0.01, Student’s t-test.
Figure 4—figure supplement 2
Neutral-red staining of phagocytic cell lineages in control and irf8 CRISPR-injected zebrafish larvae.
(A, B) Images of neutral red staining in control (A) and irf8 CRISPR/Cas9-injected (B) zebrafish larvae at 8 days post fertilization (dpf), A’ and B’ highlight boxed regions. Black arrows highlight examples of neutral red foci. (C) Quantification of neutral red foci. *p<0.01, n=4 fish for each cohort, Student’s t-test.
Figure 5 with 1 supplement
Inflammation-associated phagocytes inhibit p53EPS tumor engraftment.
(A, B) CG1 syngeneic host zebrafish at 20 days post fertilization (dpf) engrafted with p53EPS tumor cells transplanted with vehicle control (A) or Clodronate liposomes (B) at 2 dpf. (C–E) Quantification of p53EPS control engrafted and p53EPS tumors engrafted into CG1 host embryos with (C) Clodronate liposomes (p=0.0048, Fisher’s exact test, n=2 independent experiments, total 56 transplanted vehicle control and 50 transplanted Clodrosome-injected hosts), (D) engrafted into irf8 CRISPR/Cas9-injected into CG1 syngeneic host embryos (p=0.0002, Fisher’s exact test, n=2 independent experiments, total 100 transplanted control and 74 transplanted irf8 CRISPR/Cas9-injected hosts).
Figure 5—figure supplement 1
Quantitative real-time PCR analysis of control, primary tumor, and engrafted whole brains.
(A) Quantitative real-time PCR analysis of neural stem cell (NSC) genes and inflammation genes in non-tumor control brains, pooled p53EPS-burdened brains, and pooled brains engrafted with p53EPS tumor cells at 20 days post fertilization (dpf). *p<0.01 compared to non-tumor control whole brain tissue, Student’s t-test. (B) Quantitative real-time PCR analysis of NSC genes and inflammation genes at 20 dpf in primary transplanted (1T) p53EPS-burdened brains injected with vehicle control liposomes (1T p53EPS) and Clodrosomes at 2 dpf. At least five tumor-burdened brains were pooled for each cohort and expression was normalized to mScarlet mRNA expression to account for differences in tumor size. *p<0.01 compared to 1T p53EPS, Student’s t-test.
Author response image 1
Gene Set Enrichment Analysis (GSEA) for efferocytosis-associated gene expression (124 “efferocytosis” genes in GeneCards) in tp53EPS tumor brains, compared to normal zebrafish brains.
Normalized enrichment score (NES) and p-value are indicated.
Author response image 2
Dorsal views of 8 dpf zebrafish larvae engrafted with her4.1:mScarlet+ p53EPS tumor cells following treatment from 3-8dpf with 0.
Author response image 3
Control-injected tumornegative and tumor-positive Tg(mpx:EGFP) zebrafish at 10 dpf.
Videos
Video 1
Time-lapse confocal images of p53EPS brain at 12 days post fertilization (dpf) in transgenic Tg(mpeg1.1:EGFP) background.
Video 2
Time-lapse confocal images of individual her4.1:mScarlet+ p53EPS and mpeg1.1:EGFP+ cells at 12 days post fertilization (dpf).
Tables
Key resources table
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Strain, strain background (zebrafish) | CG1 | Mizgireuv and Revskoy, 2006 PMID:16540662 | ||
| Strain, strain background (zebrafish) | CG1tp53-/- | Ignatius et al., 2018 PMID:30192230 | ||
| Strain, strain background (zebrafish) | Tg(mpeg1.1:EGFP) | Ellett et al., 2011 PMID:21084797 | ||
| Strain, strain background (zebrafish) | Tg(tnfa: EGFP) | Nguyen-Chi et al., 2015 PMID:26154973 | ||
| Transfected construct (plasmid, injected) | her4.1:PI3KCAH1047R | This paper | Gateway cloning using 5' zebrafish her4.1 promoter construct (Yeo et al., 2007, PMID:17134690), middle entry PI3KCA(H1047R) ORF, and 3' polyA into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was linearized for injection using Xho1 restriction enzyme. | |
| Transfected construct (plasmid, injected) | her4.1: mScarlet | This paper | Gateway cloning using 5' zebrafish her4.1 promoter construct (Yeo et al., 2007, PMID:17134690), middle entry mScarlet ORF, and 3' polyA into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was linearized for injection using Xho1 restriction enzyme. | |
| Transfected construct (plasmid, injected) | her4.1: EGFRvIII | This paper | Gateway cloning using 5' zebrafish her4.1 promoter construct (Yeo et al., 2007, PMID:17134690), middle entry EGFR(vIII) ORF, and 3' polyA into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was linearized for injection using Xho1 restriction enzyme. | |
| Transfected construct (plasmid, injected) | her4.1: KRASG12D | This paper | Gateway cloning using 5' zebrafish her4.1 promoter construct (Yeo et al., 2007, PMID:17937395), middle entry KRAS(G12D) ORF, and 3' polyA into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was linearized for injection using Xho1 restriction enzyme. | |
| Transfected construct (plasmid, injected) | her4.1: EGFP | This paper | Gateway cloning using 5' zebrafish her4.1 promoter construct (Yeo et al., 2007, PMID:17134690), middle entry EGFP ORF, and 3' polyA into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was linearized for injection using Xho1 restriction enzyme. | |
| Transfected construct (plasmid, injected) | her4.1: Cas9-2A- EGFP | This paper | Gateway cloning using 5' zebrafish her4.1 promoter construct (Yeo et al., 2007, PMID:17134690), middle entry Cas9 ORF, and 3' 2A-EGFP into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was injected with Tol2 transposase mRNA to establish stable transgenic lines. | |
| Transfected construct (plasmid, injected) | gfap: EGFP | This paper | Gateway cloning using 5' zebrafish gfap promoter construct (Don et al., 2017, PMID:27631880), middle entry EGFP ORF, and 3' polyA into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was linearized for injection using Cla1 restriction enzyme. | |
| Transfected construct (plasmid, injected) | gfap: mScarlet | This paper | Gateway cloning using 5' zebrafish gfap promoter construct (Don et al., 2017, PMID:27631880), middle entry mScarlet ORF, and 3' polyA into a Tol2-compatible Destination vector (Tol2kit, Kwan et al., 2007, PMID:17937395). Plasmid was linearized for injection using Cla1 restriction enzyme. | |
| Transfected Construct (plasmid, injected) | mpeg1.1: EGFP | Ellett et al., 2011 PMID:21084797 | Plasmid was linearized for injection using Xho1 restriction enzyme. | |
| Transfected construct (plasmid, injected) | rag2: EGFP | Langenau et al., 2007 PMID:17510286 | Plasmid was linearized for injection using Xho1 restriction enzyme. | |
| Antibody | Anti-PCNA (rabbit monoclonal) | Cell Signaling | D3H8P | Antibody was used for IHC at 1/200 dilution |
| Antibody | Anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (rabbit polyclonal) | Cell Signaling | 9101 | Antibody was used for IHC at 1/200 dilution |
| Antibody | Anti-phospho-AKT (Ser473) (rabbit polyclonal) | Cell Signaling | 9271 | Antibody was used for IHC at 1/300 dilution |
| Sequence-based reagent | EGFP HCR probe | Clontech | Molecular Instruments | |
| Sequence-based reagent | Irf7 HCR probe | Sigma-Aldrich | Molecular Instruments | |
| Peptide, recombinant protein | Cas9 protein with NLS | PNA-Bio | CP01-200 | |
| Commercial assay of kit | In vitro sgRNA synthesis kit | New England Biolabs | E3322V | Individual sgRNA target sites are indicated in Supplementary file 7 |
| Chemical compound, drug | Clodronate lipsomes (Clodrosomes) | Encapsula Nano Sciences | CLD-8901 |
Additional files
-
Supplementary file 1
Differential gene expression (from DESeq2) of p53EPS tumor-burdened whole brain samples compared to tumor-negative samples (n=3 independent samples per cohort).
Genes with 1>log2foldChange>–1, adjusted p-value<0.05 are shown.
- https://cdn.elifesciences.org/articles/93077/elife-93077-supp1-v1.xlsx
-
Supplementary file 2
Differential gene expression (from DESeq2) of p53EPS tumor-burdened whole brain samples, compared to tumor-negative samples (n=3 independent samples per cohort) with corresponding human homologues.
Genes with 1>log2foldChange>–1, adjusted p-value<0.05 are shown.
- https://cdn.elifesciences.org/articles/93077/elife-93077-supp2-v1.xlsx
-
Supplementary file 3
Results of gene set enrichment analysis (GSEA) for published glioblastoma subtype gene sets (McLendon et al., 2008; Wang et al., 2017).
- https://cdn.elifesciences.org/articles/93077/elife-93077-supp3-v1.xlsx
-
Supplementary file 4
Results of gene set enrichment analysis (GSEA) for Hallmark gene sets (Villanueva et al., 2011).
- https://cdn.elifesciences.org/articles/93077/elife-93077-supp4-v1.xlsx
-
Supplementary file 5
Differential gene expression (from DESeq2) of mScarlet-sorted p53EPS tumor cells, compared to tumor-negative whole brain samples (n=1 pooled sorted cell sample versus n=3 independent tumor-negative controls).
- https://cdn.elifesciences.org/articles/93077/elife-93077-supp5-v1.xlsx
-
Supplementary file 6
Results of gene set enrichment analysis (GSEA) for C7: immunologic signature gene sets and GSE5099 gene sets from the Molecular Signatures Database (Villanueva et al., 2011).
- https://cdn.elifesciences.org/articles/93077/elife-93077-supp6-v1.xlsx
-
Supplementary file 7
List of oligo sequences used for quantitative RT-PCR, sgRNA synthesis, genotyping, and gene target validation.
- https://cdn.elifesciences.org/articles/93077/elife-93077-supp7-v1.xlsx
-
MDAR checklist
- https://cdn.elifesciences.org/articles/93077/elife-93077-mdarchecklist1-v1.pdf
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
A syngeneic spontaneous zebrafish model of tp53-deficient, EGFRvIII, and PI3KCAH1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapse in vivo
eLife 13:RP93077.
https://doi.org/10.7554/eLife.93077.3
